IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-9.51%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$486M
AUM Growth
+$486M
(+27%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
29.12%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
86
New
15
Increased
40
Reduced
9
Closed
21
Top Buys
| 1 |
Eli Lilly
LLY
|
$23.7M |
| 2 |
Sanofi
SNY
|
$17.5M |
| 3 |
Centene
CNC
|
$16.9M |
| 4 |
McKesson
MCK
|
$13.6M |
| 5 |
DexCom
DXCM
|
$12.4M |
Top Sells
| 1 |
Pfizer
PFE
|
$15.5M |
| 2 |
Globus Medical
GMED
|
$13.3M |
| 3 |
Acadia Healthcare
ACHC
|
$9.83M |
| 4 |
AMED
Amedisys
AMED
|
$6.89M |
| 5 |
Cigna
CI
|
$5.99M |
Sector Composition
| 1 | Healthcare | 97.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Icon
ICLR
$14B
| $6.79M | 1.4% |
+31,311
| New | +$6.79M |
|
27
uniQure
QURE
$954M
| $6.58M | 1.35% |
353,106
+183,106
| +108% | +$3.41M |
|
|
BPMC
28
DELISTED
Blueprint Medicines
BPMC
| $6.57M | 1.35% |
130,000
-23,000
| -15% | -$1.16M |
|
29
iRhythm Technologies
IRTC
$5.67B
| $6.2M | 1.28% |
57,403
-2,597
| -4% | -$281K |
|
|
ONEM
30
DELISTED
1Life Healthcare, Inc. Common Stock
ONEM
| $5.73M | 1.18% |
730,582
+230,582
| +46% | +$1.81M |
|
31
Moderna
MRNA
$9.36B
| $5.71M | 1.18% |
+40,000
| New | +$5.71M |
|
|
SGEN
32
DELISTED
Seagen Inc. Common Stock
SGEN
| $5.54M | 1.14% |
31,311
-18,689
| -37% | -$3.31M |
|
33
Zai Lab
ZLAB
$3.48B
| $5.43M | 1.12% |
156,554
+81,554
| +109% | +$2.83M |
|
34
Agilon Health
AGL
$497M
| $5.04M | 1.04% |
230,655
+55,655
| +32% | +$1.21M |
|
35
CRISPR Therapeutics
CRSP
$4.82B
| $4.86M | 1% |
80,010
-39,990
| -33% | -$2.43M |
|
36
Apellis Pharmaceuticals
APLS
$3.51B
| $4.48M | 0.92% |
99,150
+59,381
| +149% | +$2.69M |
|
|
ITCI
37
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $4.47M | 0.92% |
78,277
+38,277
| +96% | +$2.18M |
|
38
Zimmer Biomet
ZBH
$20.8B
| $4.39M | 0.9% |
41,748
+11,748
| +39% | +$1.23M |
|
39
Intellia Therapeutics
NTLA
$1.26B
| $4.32M | 0.89% |
83,495
+33,495
| +67% | +$1.73M |
|
40
PTC Therapeutics
PTCT
$4.41B
| $4.19M | 0.86% |
104,656
+62,656
| +149% | +$2.51M |
|
41
DaVita
DVA
$9.72B
| $4.17M | 0.86% |
+52,184
| New | +$4.17M |
|
42
Teladoc Health
TDOC
$1.37B
| $4.13M | 0.85% |
+124,369
| New | +$4.13M |
|
43
Aclaris Therapeutics
ACRS
$223M
| $3.99M | 0.82% |
285,971
+47,971
| +20% | +$670K |
|
44
Replimune Group
REPL
$460M
| $3.83M | 0.79% |
219,194
+54,194
| +33% | +$947K |
|
45
Mirum Pharmaceuticals
MIRM
$3.75B
| $3.45M | 0.71% |
177,427
+37,427
| +27% | +$728K |
|
|
NVRO
46
DELISTED
NEVRO CORP.
NVRO
| $3.43M | 0.71% |
78,277
+28,277
| +57% | +$1.24M |
|
47
Krystal Biotech
KRYS
$4.35B
| $3.43M | 0.7% |
+52,184
| New | +$3.43M |
|
48
Jazz Pharmaceuticals
JAZZ
$7.99B
| $3.26M | 0.67% |
20,874
-14,126
| -40% | -$2.2M |
|
|
ITOS
49
DELISTED
iTeos Therapeutics
ITOS
| $3.23M | 0.66% |
156,553
+71,553
| +84% | +$1.47M |
|
|
RETA
50
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $3.17M | 0.65% |
104,369
+69,369
| +198% | +$2.11M |
|